Treatment of glycogen storage disease type II

ABSTRACT

Methods of treating glycogen storage disease type II, by administering acid α-glucosidase, are described, as are compositions for use in treatment of glycogen storage disease type II.

This application is a continuation of U.S. application Ser. No.14/485,071, filed Sep. 12, 2014 (allowed), which is a continuation ofU.S. application Ser. No. 13/593,148, filed Aug. 23, 2012 (issued asU.S. Pat. No. 8,900,552), which is a continuation of U.S. applicationSer. No. 13/064,556, filed Mar. 30, 2011 (abandoned), which is acontinuation of U.S. application Ser. No. 12/604,267, filed Oct. 22,2009 (abandoned), which is a continuation of U.S. application Ser. No.11/889,457, filed Aug. 13, 2007 (abandoned), which is a continuation ofU.S. application Ser. No. 11/039,281, filed Jan. 20, 2005 (abandoned),which is a continuation of U.S. application Ser. No. 09/902,461, filedJul. 10, 2001 (issued as U.S. Pat. No. 7,056,712), which claims thebenefit of U.S. Provisional Application No. 60/219,237, filed Jul. 18,2000, the entire contents of each of which are hereby incorporated byreference in this application.

BACKGROUND OF THE INVENTION

Glycogen storage disease type II (GSD-II) (also known as Pompe diseaseor acid maltase deficiency) is a fatal genetic muscle disorder caused bya deficiency of acid α-glucosidase (GAA), a glycogen degrading lysosomalenzyme (Hirschhorn, R., “Glycogen storage disease type II: acidα-glucosidase (acid maltase) deficiency”, in Scriver, C. R. et al.,(eds) The Metabolic and Molecular Basis of Inherited disease, 7^(th)Ed., McGraw-Hill, New York, 1995, pp. 2443-2464). The deficiency resultsin lysosomal glycogen accumulation in almost all tissues of the body,with cardiac and skeletal muscle being the most seriously affected. Thecombined incidence of all forms of GSD-II is estimated to be 1:40,000,and the disease affects all groups without an ethnic predilection(Martiniuk, F. et al., Amer. J. Med. Genet. 79:69-72 (1998); Ausems, M.G. E. M. et al., Eur. J. Hum. Genet. 7:713-716 (1999)).

Clinically, GSD-II encompasses a range of phenotypes differing as to ageof onset, organs involved and clinical severity, generally correlatingwith the residual amount of GAA activity. In its most severepresentation (infantile GSD-II, or Pompe disease, in which less than 1%of normal GAA activity is present), infants are affected by ahypertrophic cardiomyopathy, generalized muscle weakness and hypotoniasecondary to massive glycogen accumulation in cardiac and skeletalmuscles (for review, see Hirschhorn, supra). The disease progressesrapidly, with death from cardiac failure usually occurring by 1 year ofage. Juvenile (1-10% of normal GAA activity) and adult-onset (10-40% ofnormal GAA activity) faints of the disease are characterized by lack ofsevere cardiac involvement, later age of onset, and slower progression,but eventual respiratory or limb muscle involvement results insignificant morbidity and mortality for the affected individuals.

Drug treatment strategies, dietary manipulations, and bone marrowtransplantation have been employed as means for treatment for GSD-II,without significant success (Hug, G. et al., Birth Defects Org. Ser.9:160-183 (1967); Slonim, A. E. et al., Neurology 33:34 (1983); Watson,J. G. et al., N. Engl. J. Med. 314:385 (1986)). Early attempts at enzymereplacement were also unsuccessful (Hug, G. and Schubert, W. K., J.Clin. Invest. 46:1073 (1967); de Barsy, T. et al., Birth Defects Orig.Art. Ser. 9:84-190 (1973); Williams, J. C. and Murray, A. K., “Enzymereplacement in Pompe disease with an alpha glucosidase low-densitylipoprotein complex”, in Desnick, R. J. (ed), Enzyme Therapy in GeneticDiseases: 2, New York, Alan R. Liss 1980; pp. 415-423)). A need remainsfor effective treatment of GSD-II.

SUMMARY OF THE INVENTION

The present invention is drawn to methods of treating glycogen storagedisease type II (infantile, juvenile or adult-onset) in an individual,by administering to the individual a therapeutically effective amount ofacid α-glucosidase (e.g., less than about 15 mg enzyme per kilogram ofbody weight, preferably about 1-10 mg enzyme per kilogram of bodyweight, more preferably about 10 enzyme per kilogram of body weight orabout 5 mg enzyme per kilogram of body weight), at a regular interval(e.g., monthly, bimonthly, weekly, twice weekly, daily). The acidα-glucosidase is human acid α-glucosidase, preferably recombinant humanacid α-glucosidase, more preferably, precursor form of human acidα-glucosidase, and even more preferably precursor form of human acidα-glucosidase produced in Chinese hamster ovary cells. The acidα-glucosidase is administered periodically (e.g., monthly, bimonthly,weekly, twice weekly, daily). In preferred embodiments, the acidα-glucosidase is administered intravenously; intramuscularly;intrathecally; or intraventricularly.

The methods of the invention provide the first effective means to treatan individual with glycogen storage disease type II.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1A-1C are a series of graphic representations depictinglongitudinal data (for the first 16 months of age) on motor developmentas assessed by Alberta Infant Motor Scale (AIMS) (closed diamonds), andtiter of antibodies to recombinant human acid α-glucosidase (rhGAA)(open diamonds) in three patients (patient 1, FIG. 1A; patient 2, FIG.1B; patient 3, FIG. 1C) with infantile Pompe disease receiving enzymereplacement therapy. The arrow indicates when the enzyme therapy wasinitiated. AIMS scores in normal patients are plotted as dotted curvesagainst age (5^(th), 10^(th), 25^(th), 50^(th), 75^(th) and 95^(th)percentile, from bottom to top).

FIG. 2A-2F are a series of graphic representations depictinglongitudinal two-dimensional echocardiographic measurements of leftventricular volume (FIG. 2A-2C) and mass (FIG. 2D-2F) in the threeinfantile Pompe disease patients receiving enzyme replacement therapy(patient 1, FIGS. 2A and 2D; patient 2, FIGS. 2B and 2E; patient 3,FIGS. 2C and 2F). Week 0 depicts the measurements at the time of enzymetherapy initiation. Open diamonds, end-diastolic volume measurement;closed diamonds, end-systolic volume measurement.

DETAILED DESCRIPTION OF THE INVENTION

The present invention is drawn to methods of treating glycogen storagedisease type II (GSD-II) in an individual, by administering the enzyme,acid α-glucosidase (GAA) to the individual, as well as the use of theenzyme, GAA, in the manufacture of a medicament for the treatment ofglycogen storage disease type II. As described herein, Applicants havesuccessfully treated infants suffering from GSD-II by administering GAAto the infants on a regular basis; the infants demonstrated improvementof cardiac status, pulmonary function, and neurodevelopment, as well asreduction of glycogen levels in tissue.

As a result of these findings, it is now possible for the first time totreat GSD-II, including infantile, juvenile and adult-onset GSD-II.Although the results described herein discuss individuals with the mostsevere form of GSD-II (infantile GSD-II), it is expected that themethods will be equally effective in individuals affected by juvenile oradult-onset GSD-II, and may, in fact, be even more effective, asindividuals with juvenile or adult-onset GSD-II have higher levels ofresidual GAA activity (1-10%, or 10-40%, respectively), and thereforeare likely to be more immunologically tolerant of the administered GAA(e.g., they are generally cross-reactive immunoreactive material(CRIM)-positive for endogenous GAA, so that their immune systems do notperceive the GAA as a “foreign” protein, and they do not developanti-GAA antibodies). The enhanced efficacy in such individuals can beseen in patient 3, who was CRIM-positive and did not develop anti-GAAantibodies, and who demonstrated a normal progression of developmentalmilestones, in contrast with the variable course that was seen inCRIM-negative patients 1 and 2 (who did develop anti-GAA antibodies).

The terms, “treat” and “treatment,” as used herein, refer toamelioration of one or more symptoms associated with the disease,prevention or delay of the onset of one or more symptoms of the disease,and/or lessening of the severity or frequency of one or more symptoms ofthe disease. For example, treatment can refer to improvement of cardiacstatus (e.g., increase of end-diastolic and/or end-systolic volumes, orreduction, amelioration or prevention of the progressive cardiomyopathythat is typically found in GSD-II) or of pulmonary function (e.g.,increase in crying vital capacity over baseline capacity, and/ornormalization of oxygen desaturation during crying); improvement inneurodevelopment and/or motor skills (e.g., increase in AIMS score);reduction of glycogen levels in tissue of the individual affected by thedisease; or any combination of these effects. In one preferredembodiment, treatment includes improvement of cardiac status,particularly in reduction or prevention of GSD-II-associatedcardiomyopathy. The terms, “improve,” “increase” or “reduce,” as usedherein, indicate values that are relative to a baseline measurement,such as a measurement in the same individual prior to initiation of thetreatment described herein, or a measurement in a control individual (ormultiple control individuals) in the absence of the treatment describedherein. A control individual is an individual afflicted with the sameform of GSD-II (either infantile, juvenile or adult-onset) as theindividual being treated, who is about the same age as the individualbeing treated (to ensure that the stages of the disease in the treatedindividual and the control individual(s) are comparable).

The individual being treated is an individual (fetus, child, adolescent,or adult human) having GSD-II (i.e., either infantile GSD-II, juvenileGSD-II, or adult-onset GSD-II). The individual can have residual GAAactivity, or no measurable activity. For example, the individual havingGSD-II can have GAA activity that is less than about 1% of normal GAAactivity (infantile GSD-II), GAA activity that is about 1-10% of normalGAA activity (juvenile GSD-II), or GAA activity that is about 10-40% ofnormal GAA activity (adult GSD-II). The individual can be CRIM-positiveor CRIM-negative for endogenous GAA. In a preferred embodiment, theindividual is CRIM-positive for endogenous GAA. In another preferredembodiment, the individual is an individual who has been recentlydiagnosed with the disease. Early treatment (treatment commencing assoon as possible after diagnosis) is important for to minimize theeffects of the disease and to maximize the benefits of treatment.

In the methods of the invention, human acid α-glucosidase (GAA) isadministered to the individual. The GAA is in a form that, whenadministered, targets tissues such as the tissues affected by thedisease (e.g., heart, muscle). In one preferred embodiment, the humanGAA is administered in its precursor form, as the precursor containsmotifs which allow efficient receptor-mediated uptake of GAA.Alternatively, a mature form of human GAA that has been modified tocontain motifs to allow efficient uptake of GAA, can be administered. Ina particularly preferred embodiment, the GAA is the precursor form ofrecombinant human GAA.

GAA is obtainable from a variety of sources. In a particularly preferredembodiment, recombinant human acid α-glucosidase (rhGAA) has beenproduced in Chinese hamster ovary (CHO) cell cultures is used (see,e.g., Fuller, M. et al., Eur. J. Biochem. 234:903-909 (1995); Van Hove,J. L. K. et al., Proc. Natl. Acad. Sci. USA 93:65-70 (1996); the entireteachings of these references are incorporated herein by reference).Production of GAA in CHO cells appears to yield a product havingglycosylation which allows significant and efficient uptake of GAA inthe desired tissues (heart and muscle); it is assumed that theglycosylation differs from that of GAA that is produced in transgenicmouse and rabbit milk (see, e.g., Bijvoet, A. G. A. et al., Hum. Mol.Genet. 7:1815-1824 (1998); Bijvoet, A. G. A. et al., Hum. Mol. Genet.8:2145-2153 (1999)).

The GAA has a specific enzyme activity in the range of about 1.0-3.5μmol/min/mg protein, preferably in the range of about 2-3.5 μmol/min/mgprotein. In one preferred embodiment, the GAA has a specific enzymeactivity of at least about 1.0 μmol/min/mg protein; more preferably, aspecific enzyme activity of at least about 2.0 μmol/min/mg protein; evenmore preferably, a specific enzyme activity of at least about 2.5μmol/min/mg protein; and still more preferably, a specific enzymeactivity of at least about 2.75 μmol/min/mg protein.

GAA can be administered alone, or in compositions or medicamentscomprising the GAA (e.g., in the manufacture of a medicament for thetreatment of the disease), as described herein. The compositions can beformulated with a physiologically acceptable carrier or excipient toprepare a pharmaceutical composition. The carrier and composition can besterile. The formulation should suit the mode of administration.

Suitable pharmaceutically acceptable carriers include but are notlimited to water, salt solutions (e.g., NaCl), saline, buffered saline,alcohols, glycerol, ethanol, gum arabic, vegetable oils, benzylalcohols, polyethylene glycols, gelatin, carbohydrates such as lactose,amylose or starch, sugars such as mannitol, sucrose, or others,dextrose, magnesium stearate, talc, silicic acid, viscous paraffin,perfume oil, fatty acid esters, hydroxymethylcellulose, polyvinylpyrolidone, etc., as well as combinations thereof. The pharmaceuticalpreparations can, if desired, be mixed with auxiliary agents, e.g.,lubricants, preservatives, stabilizers, wetting agents, emulsifiers,salts for influencing osmotic pressure, buffers, coloring, flavoringand/or aromatic substances and the like which do not deleteriously reactwith the active compounds. In a preferred embodiment, a water-solublecarrier suitable for intravenous administration is used.

The composition or medicament, if desired, can also contain minoramounts of wetting or emulsifying agents, or pH buffering agents. Thecomposition can be a liquid solution, suspension, emulsion, tablet,pill, capsule, sustained release formulation, or powder. The compositioncan also be formulated as a suppository, with traditional binders andcarriers such as triglycerides. Oral formulation can include standardcarriers such as pharmaceutical grades of mannitol, lactose, starch,magnesium stearate, polyvinyl pyrollidone, sodium saccharine, cellulose,magnesium carbonate, etc.

The composition or medicament can be formulated in accordance with theroutine procedures as a pharmaceutical composition adapted foradministration to human beings. For example, in a preferred embodiment,a composition for intravenous administration typically is a solution insterile isotonic aqueous buffer. Where necessary, the composition mayalso include a solubilizing agent and a local anesthetic to ease pain atthe site of the injection. Generally, the ingredients are suppliedeither separately or mixed together in unit dosage form, for example, asa dry lyophilized powder or water free concentrate in a hermeticallysealed container such as an ampule or sachette indicating the quantityof active agent. Where the composition is to be administered byinfusion, it can be dispensed with an infusion bottle containing sterilepharmaceutical grade water, saline or dextrose/water. Where thecomposition is administered by injection, an ampule of sterile water forinjection or saline can be provided so that the ingredients may be mixedprior to administration.

The GAA can be formulated as neutral or salt forms. Pharmaceuticallyacceptable salts include those formed with free amino groups such asthose derived from hydrochloric, phosphoric, acetic, oxalic, tartaricacids, etc., and those formed with free carboxyl groups such as thosederived from sodium, potassium, ammonium, calcium, ferric hydroxides,isopropylamine, triethylamine, 2-ethylamino ethanol, histidine,procaine, etc.

GAA (or composition or medicament containing GAA) is administered by anappropriate route. In one embodiment, the GAA is administeredintravenously. In other embodiments, GAA is administered by directadministration to a target tissue, such as heart or muscle (e.g.,intramuscular), or nervous system (e.g., direct injection into thebrain; intraventricularly; intrathecally). More than one route can beused concurrently, if desired.

GAA (or composition or medicament containing GAA) can be administeredalone, or in conjunction with other agents, such as antihistamines(e.g., diphenhydramine) or immunosuppressants or other immunotherapeuticagents which counteract anti-GAA antibodies. The term, “in conjunctionwith,” indicates that the agent is administered at about the same timeas the GAA (or composition containing GAA). For example, the agent canbe mixed into a composition containing GAA, and thereby administeredcontemporaneously with the GAA; alternatively, the agent can beadministered contemporaneously, without mixing (e.g., by “piggybacking”delivery of the agent on the intravenous line by which the GAA is alsoadministered, or vice versa). In another example, the agent can beadministered separately (e.g., not admixed), but within a short timeframe (e.g., within 24 hours) of administration of the GAA. In onepreferred embodiment, if the individual is CRIM-negative for endogenousGAA, GAA (or composition containing GAA) is administered in conjunctionwith an immunosuppressive or immunotherapeutic regimen designed toreduce amounts of, or prevent production of, anti-GAA antibodies. Forexample, a protocol similar to those used in hemophilia patients(Nilsson, I. M. et al., N. Engl. J. Med. 318:947-50 (1988)) can be usedto reduce anti-GAA antibodies. Such a regimen can also be used inindividuals who are CRIM-positive for endogenous GAA but who have, orare at risk of having, anti-GAA antibodies. In a particularly preferredembodiment, the immunosuppressive or immunotherapeutic regimen is begunprior to the first administration of GAA, in order to minimize thepossibility of production of anti-GAA antibodies.

GAA (or composition or medicament containing GAA) is administered in atherapeutically effective amount (i.e., a dosage amount that, whenadministered at regular intervals, is sufficient to treat the disease,such as by ameliorating symptoms associated with the disease, preventingor delaying the onset of the disease, and/or also lessening the severityor frequency of symptoms of the disease, as described above). The amountwhich will be therapeutically effective in the treatment the diseasewill depend on the nature and extent of the disease's effects, and canbe determined by standard clinical techniques. In addition, in vitro orin vivo assays may optionally be employed to help identify optimaldosage ranges. The precise dose to be employed will also depend on theroute of administration, and the seriousness of the disease, and shouldbe decided according to the judgment of a practitioner and each patientscircumstances. Effective doses may be extrapolated from dose-responsecurves derived from in vitro or animal model test systems. In apreferred embodiment, the therapeutically effective amount is less thanabout 15 mg enzyme/kg body weight of the individual, preferably in therange of about 1-10 mg enzyme/kg body weight, and even more preferablyabout 10 mg enzyme/kg body weight or about 5 mg enzyme/kg body weight.The effective dose for a particular individual can be varied (e.g.,increased or decreased) over time, depending on the needs of theindividual. For example, in times of physical illness or stress, or ifanti-GAA antibodies become present or increase, or if disease symptomsworsen, the amount can be increased.

The therapeutically effective amount of GAA (or composition ormedicament containing GAA) is administered at regular intervals,depending on the nature and extent of the disease's effects, and on anongoing basis. Administration at a “regular interval,” as used herein,indicates that the therapeutically effective amount is administeredperiodically (as distinguished from a one-time dose). The interval canbe determined by standard clinical techniques. In preferred embodiments,GAA is administered monthly, bimonthly; weekly; twice weekly; or daily.The administration interval for a single individual need not be a fixedinterval, but can be varied over time, depending on the needs of theindividual. For example, in times of physical illness or stress, ifanti-GAA antibodies become present or increase, or if disease symptomsworsen, the interval between doses can be decreased.

In one preferred embodiment, a therapeutically effective amount of 10 mgenzyme/kg body weight is administered weekly. In another preferredembodiment, a therapeutically effective amount of 5 mg enzyme/kg bodyweight is administered twice weekly.

The invention additionally pertains to a pharmaceutical compositioncomprising human acid α-glucosidase, as described herein, in a container(e.g., a vial, bottle, bag for intravenous administration, syringe,etc.) with a label containing instructions for administration of thecomposition for treatment of glycogen storage disease type II, such asby the methods described herein.

The invention will be further and more specifically described by thefollowing examples.

EXEMPLIFICATION Phase I/II Trial of Use of Recombinant Human Acidα-Glucosidase

Material and Methods

Patients:

Inclusion criteria were infants affected with infantile GSD-II havingvirtually absent GAA activity (<1% of normal in skin fibroblasts and/ormuscle biopsy) and less than one year of age. Exclusion criteriaincluded severe cardiorespiratory failure at baseline and/or othermedical conditions likely to decrease survival. Because of the limitedlife expectancy of the disease following diagnosis, no placebo controlwas used. Historical control data indicated that virtually all patientsdied before 1 year of age (Table 1).

TABLE 1 Historical control data of infantile glycogen storage disease,type II Length of disease Onset (months) Death (months) course (months)Duke University Medical Center (n = 30)* Mean ± SD 5.1 ± 1.8 8.6 ± 2.43.5 ± 2.3 Range  2.4-10.3 3.3-12.4 0.0-9.0 Slonim et al. (n = 10)** Mean± SD 2.5 ± 1.0 7.2 ± 2.8 4.7 ± 2.4 Range 1.0-4.0 4.0-12.0 2.0-9.0 *Datafrom Duke University Pompe Disease Registry **Data from Slonim et al.,J. Pediatr. 137:283-285 (2000).

Three infants affected with infantile GSD-II as evidenced by reducedacid α-glucosidase activity to less than 1% of normal in skinfibroblasts and/or muscle biopsy were enrolled in the study. At theprotein level, both patients 1 and 2 had no detectable GAA protein whilepatient 3 had reduced levels of GAA protein detected by immunoblotanalysis. The baseline clinical data before the initiation of thetherapy are summarized in Table 2.

TABLE 2 Baseline Clinical Data on 3 Infantile Pompe Disease PatientsPatient Age Motor GAA Activity in Number/ Ethnic rhGAA Development SkinFibroblasts CRIM* Current Sex Background Started Cardiac StatusPulmonary Function (AIMS Score) (% of normal) Status Age PatientCaucasian 4 months Severe Borderline normal, <<5^(th)% 0.84% Negative 29months 1/male cardiomyopathy; left main bronchus status post compressiondue to cardiac arrest markedly enlarged heart, O₂ desaturation PatientAfrican- 3 months Moderate O₂ desaturation during  <5^(th)% 0.57%Negative 25 months 2/male American cardiomyopathy crying PatientCaucasian 2½ months Borderline Normal <<5^(th)% 0.69% Positive 23 months3/male cardiomyopathy *CRIM = cross reactive immunoreactive materialPatient 1 presented at 2 months of age with cardiac arrest duringelective surgical repair of an inguinal hernia. Subsequent evaluationwhen he was 4 months of age demonstrated evidence of severe hypotonia,with a motor development age estimated to be equivalent to that of a 3week old. He also had profound cardiomyopathy and severe cardiomegalywith compression of the left main bronchus resulting in partialatelectasis of the left lung, and feeding difficulties and failure tothrive. Patients 2 and 3 were prenatally diagnosed with Pompe disease;importantly, each had a previous sibling that had died of symptomstypically attributable to the infantile GSD-II. Both patients hadevidence of motor delays; in addition patient 2 had feeding difficulty,failure to thrive and severe cardiomyopathy.

Basic Design:

The study was designed as a Phase I/II, open-label, single-dose, safetyand efficacy study of rhGAA administered twice weekly in the 3 patientswith infantile Pompe disease. The study was approved by theinstitutional review board, and parental written informed consent wasobtained.

The study consisted of an initial Screening Phase, a 13-week TreatmentPhase, and a Follow-up Treatment Phase. During the Screening Phase theinitial clinical status of the patients was assessed; in addition, GAAand glycogen levels were determined in skeletal muscle biopsy samples.During the Treatment Phase, patients received intravenous infusions ofrhGAA (5 mg/kg) twice weekly. Patients were closely monitored for anyadverse responses to the enzyme infusions, as well as for any impact therhGAA administrations had on the clinical progression of infantileGSD-II. General clinical assessments included routine physicalexaminations, supplemented by complete urine, hematological, andclinical chemistry analyses (electrolytes, glucose, creatinine, BUN,CO₂, protein, albumin, ALT, AST, bilirubin, alkaline phosphatase, CK andisozyme, uric acid). Exhaustive neurologic and motor functionevaluations included manual muscle strength testing, Denver developmenttesting, and AIMS (Alberta Infant Motor Scale; see Piper, M. C. andDarrah, J., Motor Assessment of the Developing Infant, WB SandersCompany, Philadelphia, 1994). Two-dimensional, M-mode and Dopplerechocardiography were used to assess left ventricular mass, wallthickness and systolic as well as diastolic functions. Additionally, avariety of pulmonary functions (crying vital capacity, trendpulse-oximetry and end tidal carbon dioxide measurement, as well asnegative inspiratory force maneuver) were monitored throughout thestudy. At the conclusion of the 13-week treatment phase, GAA activity,glycogen levels and histopathology of muscle biopsies obtained from thequadriceps muscles of the contra-lateral thigh of the pre-treatmentbiopsies were determined. The muscle biopsies were taken 3 days afterthe rhGAA infusion.

Enzyme Source:

rhGAA purified from the culture medium of rhGAA secreting CHO cells (VanHove, J. L. K. et al., Proc. Natl. Acad. Sci. USA 93:65-70 (1996)) wasprovided as a GMP-grade, sterile and colorless solution by Synpac (NorthCarolina), Inc., 99 Alexander Drive, Suite NW20, Research Triangle Park,N.C. 27709. rhGAA was purified primarily as the 110-RD precursor proteinwith specific enzyme activity of 2.77-3.02 μmol/min/mg protein.

ELISA for Anti-rhGAA Antibodies:

The ELISA for anti-rhGAA antibodies was a standard sandwich assayperformed by Phoenix International Life Sciences, Inc. (Saint-Laurent,Quebec). Briefly, microliter plates were coated with rhGAA at 2.0 μg/mlovernight and then blocked with bovine IgG. Patient serum, diluted to1:100 and then serially diluted at 1:2, was reacted with the rhGAA onthe plate. The amount of bound antibody was detected with a horseradishperoxidase conjugated goat anti-human secondary antibody andtetramethylbenzidine substrate by measuring the absorbances at 450 nm.Positive samples were defined as having an absorbance that was higherthan the negative cutoff. This was defined as twice the A450 value ofthe normal human serum negative control. Titer was defined as thedilution of the serum that still had an A450 reading above the negativecutoff value.

GAA Activity, Glycogen Content and Western Blot Analysis:

GAA activity was assessed by measurement of4-methyl-umbelliferyl-α-D-glucoside cleavage at pH 4.3 as previouslydescribed (Reuser, A. J. J. et al., Am. J. Hum. Genet. 30:132-143(1978)). As an internal standard, acid-β-galactosidase activity wassimilarly assayed with the 4-methyl-umbilliferyl derivative as thesubstrate (Wenger, D. A. and Williams, C., “Screening for lysosomaldisorders” in Hommes, F. A. (ed.), Techniques in diagnostic humanbiochemical genetics: a laboratory manual, Wiley-Liss, New York, 1991,pp. 587-617). Glycogen content was determined by treatment of tissueextracts with A. niger amyloglucosidase and measurement of glucosereleased (Van Hove, J. L. K. et al., Proc. Natl. Acad. Sci. USA 93:65-70(1996)). Western blot analysis was performed with antibody raised inrabbits against purified placenta GAA (Van Hove, J. L. K. et al.,supra).

Histology:

One specimen of muscle was mounted on a chuck with gum tragacanth andquick-frozen in isopentane cooled by liquid nitrogen. Five micronsections were obtained and stained with hematoxylin and eosin, modifiedGomori trichrome, ATPase at pH 4.35 and 9.4, nicotinamide dehydrogenasetetrazolium blue reductase, and phosphorylase. A second specimen wasclamped in situ and placed in 2.5% glutaraldehyde. The tissue wasprocessed without en bloc staining with uranyl acetate in order to avoidloss of glycogen. Semithin sections (0.5 micron) were stained withtoluidine blue and thin sections stained with uranyl acetate and leadcitrate and mounted on a copper grid for electron microscopy.

Results

Patient Reaction to Treatment:

The three patients with infantile Pompe disease received twice weeklyintravenous infusions of rhGAA for 21-25 months. No serious allergicreactions occurred during enzyme therapy. However, three episodes ofskin rash, accompanied by a mild fever and increased irritabilityoccurred in two of the patients (patient 1 two episodes, patient 2single episode). These symptoms resolved promptly after intravenousadministration of diphenhydramine. After a second episode of skin rash,patient 1 was premedicated with oral diphenhydramine just prior to allsubsequent rhGAA infusions, without further episodes. Patient 2 wassimilarly premedicated with oral diphenhydramine just prior to allsubsequent infusions, without further episodes. Multiple hematologicalparameters, liver functions, renal functions, and urinalyses have allbeen in the normal range throughout the therapy period in all treatedpatients.

Anti-rhGAA antibodies of IgG class were detected in patients 1 and 2 asearly as 3 weeks after the initiation of the enzyme therapy (FIGS.1A-1C). Anti-rhGAA antibody titers increased to 1:1600 by week 16 inpatient 1 (FIG. 1A) and 1:6400-1:12,800 between weeks 11-19 in patient 2(FIG. 1B). As anti-rhGAA antibody titers increased, we noted thatclinical improvements (noted early during therapy—see below) were nolonger advancing. Neither untoward effects nor anti-rhGAA antibodieshave been detected in patient 3 (FIG. 1C).

Cardiac Status:

Prior to the initiation of the enzyme therapy, patients 1 and 2 hadsevere hypertrophic cardiomyopathy associated with an increased leftventricular (LV) mass, concentric thickening of the ventricular wall anda decrease in size of the ventricular cavity (FIG. 2B, the cavity inpatient 2 was almost obliterated at the end of systole). All of thesefeatures are typically seen in the untreated patient with the infantileform of Pompe disease. Additionally patient 2 was noted to have anincreased LV ejection fraction (shortening fraction, 84%) reflective ofa hyperdynamic shortening. None of the patients, however, had anyevidence of obstruction of the ventricular outflow tract. Thelongitudinal echocardiographic data assessed in the patients during thefirst 3 months of rhGAA therapy are shown in FIG. 2A-2C. During thetreatment period, in both patients 1 and 2, the LV end-diastolic andend-systolic volumes (2-D measurements) progressively increased, and upto almost 2-3 fold by the end of 3 months of therapy as compared tothose measured during the pre-treatment phase (FIGS. 2A and 2B,respectively). Similar increases were noted by M-mode analysis (data notshown). The two-dimensional LV mass measurements (FIG. 2D-2F) initiallyincreased as the LV volumes increased, but then steadily decreasedduring therapy, to a value that was less than the pre-treatment LV mass(reduced to 60-70% of the baseline pretreatment levels). The initialincrease in mass was most likely due to an increase in the LV volume,without any changes in the LV wall thickness. These overall improvementsin cardiac parameters, were sustained through the latest follow-upevaluation, although patient 1 required an intensive daily enzymeinfusion for 10 days when LV mass was further increased and cardiacfunction compromised at the time of viral pneumonia. Otherwise theventricular function in both patients had been normal and remainednormal at the latest follow-up. Thus, the progressive cardiac morbiditynormally noted in untreated infantile Pompe disease was clearly averted.

Patient 3 had a Lv mass of 64 g/β² (upper normal limits 65) butotherwise of normal baseline cardiac evaluation at the initiation oftherapy, and has continued to be normal (with LV mass now of 33 g/β²)since 7 months post-therapy.

Pulmonary Function:

In the first 2 months of therapy, improvement of pulmonary function wasevident by increases in crying vital capacity (improvements of greaterthan 28% and 70%, in patients 1 and 2, respectively) over baselinecapacities, and normalization of O₂ desaturation during crying (O₂saturation of 70% in patient 1 and 81% in patient 2 during maximalcrying). Decreased respiratory muscle strength was also evidenced inpatient 1 before the therapy by a negative inspiratory force maneuver(NIFM) of −45 cm H₂O. With treatment, the NIFM increased to −55 cm H₂O.The initial improvements noted in the pulmonary functions of bothpatients, however, plateaued over the next 2-3 months and declinedsubsequently, concomitant with the rising anti-rhGAA antibodies. Bothpatients have subsequently become ventilator dependent after episodes ofviral pneumonia precipitated respiratory insufficiency.

Patient 3 had a normal pulmonary function at initiation of therapy andhas continued to demonstrate normal pulmonary function testing at thelatest follow-up.

Neurodevelopment and Motor Assessment:

Alberta Infant Motor Scale (AIMS) was used to evaluate the motordevelopment in these infants. AIMS scores for all 3 patients startedbelow the 5th percentile for age (FIG. 1A-1C). Patient 1 remained belowthe 5th percentile but showed increases within that range beforebeginning to decline at week 13 of the therapy (FIG. 1A). Patient 2 roseto the 25th percentile by week 5, dropped back to remain below the 5thpercentile after week 7 despite increasing skills, then showed a rapiddecline and loss of skills between weeks 13 and 17 (FIG. 1B). The onsetof clinical declines, again was concomitant with the rising anti-rhGAAantibodies (FIG. 1A, 1B).

Concurrently administered neurologic and Denver Developmentalevaluations showed in patient 1, normal personal-social, language, andfine motor developmental domains with ongoing but improving gross motordelay until week 10 when a plateau and subsequent regression becameapparent. Importantly, gross motor skills had shown significant progressuntil week 10 but never reached normal. Patient 2 showed milddevelopmental delay in the gross motor sphere only with attainment ofnormal developmental skills in the fine motor, personal-social, andlanguage domains until weeks 14-16 when regression occurred. Currently,both patients have normal personal-social development for age but delayin all other domains.

Patient 3 showed a steady increase of AIMS score, rising over the10^(th) percentile by week 11 of the therapy and rising above the25^(th) percentile by week 20 (FIG. 1C), and 90^(th) percentile atlatest follow-up. At age 9 months, he maintained independent sitting,belly crawled reciprocally for mobility, and maintained standing withhands held. Remarkably, he has been walking independently since 12months of age and has been able to move between squatting and standingwithout hand use since 14 months of age. He currently also has normalfor age neurologic and Denver development evaluations in all domains.

Muscle GAA Activity and Glycogen Content:

Muscle biopsies were performed at baseline 1 week prior to the start ofthe rhGAA therapy except in patient 1 who had a biopsy done at the timeof diagnosis which was 2 months prior to initiation of rhGAA therapy.After 4 months of rhGAA therapy, muscle biopsies were obtained from thecontra-lateral quadriceps 3 days after the enzyme infusion (troughlevel). With rhGAA treatment GAA activity increased 2-3 fold overbaseline pre-treatment levels in both patients 1 and 2, and 18 fold inpatient 3 (Table 3).

TABLE 3 Muscle Acid α-glucosidase Activity and Glycogen Content inInfantile Pompe Disease Patients Treated with rhGAA GAA ActivityGlycogen Content nmole/hr/mg Protein % Wet Weight Patient 1 Pre-therapy0.41 5.90% Post-therapy 0.95 7.50% Patient 2 Pre-therapy 0.67 5.68%Post-therapy 1.97 4.43% Patient 3 Pre-therapy 0.1 5.13% Post-therapy1.84 1.43% Control 23.92 +/− 8.63 0.94 +/− 0.55% (upper normal limit;1.5%)The absolute level of GAA activity approached 8% of the GAA activityseen in normal muscles. There were no appreciable changes in the muscleglycogen content in patients 1 and 2, but glycogen levels were reducedto within normal range in patient 3.

Histology:

The pre-treatment biopsies of all the patients showed markedvacuolization of the muscle fibers in the frozen sections. Evaluation ofthe semithin sections demonstrated the fibers to be expanded by glycogenwith the formation of glycogen lakes. In some fibers faint outlines ofresidual membranes could be discerned. Electron microscopy confirmed thepresence of glycogen both in expanded lysosomes and lying free in thecytoplasm. The biopsy from patient 3 had more glycogen remaining withinlysosomes than did the other two patients (data not shown).

The 4-month post-treatment biopsies of patients 1 and 2 were similar tothe pre-treatment biopsies in terms of glycogen accumulation. Thepost-treatment biopsy of patient 3, however, had a marked decrease invisible glycogen and essentially normal histology in most of the musclefibers. Electron microscopy showed many remaining distended lysosomeswere depleted of glycogen. Some glycogen lakes and glycogen-richlysosomes remained.

Western Blot Analysis

To investigate why anti-rhGAA antibodies developed in patients 1 and 2,but not 3, we performed a Western blot analysis specific for detectionof expressed (but nonfunctional) GAA protein in fibroblasts derived fromeach of the patients. No GAA protein was detected in the fibroblasts ofpatients 1 and 2, whereas a readily detectable precursor form of GAAprotein (110 kD) was found in patient 3. These patterns were previouslyseen in other patients with infantile GSD-II (Van der Ploeg, A. T. etal., Am. J. Hum. Genet. 44:787-793 (1989)). Normal fibroblasts asexpected have GAA protein predominantly of 95 kD and 76 kD.

Further Studies

Three more patients have been enrolled in an additional study. All threeare CRIM positive. After treatment (10 mg/kilogram body weight, weeklyintravenous infusions of rhGAA) for 3-6 weeks, improvement of heartfunction, muscle strength, and motor development have been seen.

The teachings of all publications cited herein are incorporated hereinby reference in their entirety.

While this invention has been particularly shown and described withreference to preferred embodiments thereof, it will be understood bythose skilled in the art that various changes in form and details may bemade therein without departing from the spirit and scope of theinvention as defined by the appended claims.

I claim:
 1. A method of treating glycogen storage disease type II in ahuman in need of such treatment comprising: i) determining if said humanis cross-reactive-immunological-material negative for endogenous acidα-glucosidase (CRIM-negative), and ii) to a human determined in step (i)to be CRIM-negative, administering recombinant human acid α-glucosidasefrom Chinese hamster ovary cell culture (CHO GAA) in an amountsufficient to effect said treatment, in conjunction with animmunosuppressive or immunotherapeutic regimen.
 2. The method accordingto claim 1, wherein said immunosuppressive or immunotherapeutic regimenis administered prior to any administration of said CHO GAA.
 3. A methodof treating glycogen storage disease type II in a CRIM-negative human inneed of such treatment comprising administering CHO GAA to theCRIM-negative human in an amount sufficient to effect said treatment inconjunction with an immunosuppressive or immunotherapeutic regimen. 4.The method according to claim 3, wherein said immunosuppressive orimmunotherapeutic regimen is administered prior to any administration ofsaid CHO GAA.
 5. The method according to claim 1 or 3, wherein theglycogen storage disease type II is infantile glycogen storage diseasetype II, juvenile glycogen storage disease type II, or adult-onsetglycogen storage disease type II.
 6. The method according to claim 5,wherein the glycogen storage disease type II is infantile glycogenstorage disease type II.
 7. The method according to claim 1 or 3,wherein less than 15 mg of said CHO GAA per kilogram of body weight isadministered.
 8. The method according to claim 7, wherein 1 to 10 mg ofsaid CHO GAA per kilogram of body weight is administered.
 9. The methodaccording to claim 1 or 3, wherein said CHO GAA is the precursor form ofhuman acid α-glucosidase.
 10. The method according to claim 1 or 3,wherein said CHO GAA is administered at a regular interval.
 11. Themethod according to claim 10, wherein said CHO GAA is administeredmonthly, bimonthly, weekly, twice weekly or daily.
 12. The methodaccording to claim 11, wherein said CHO GAA is administered bimonthly.13. The method according to claim 1 or 3, wherein said CHO GAA isadministered intravenously, intramuscularly, intrathecally orintraventricularly.
 14. The method according to claim 1 or 3, whereinsaid method comprises treating cardiomyopathy associated with glycogenstorage disease type II in a human in need of such treatment.
 15. Amethod of treating glycogen storage disease type II in a CRIM-negativehuman in need of such treatment comprising administering CHO GAAbimonthly to the human in an amount sufficient to effect said treatment,in conjunction with an immunosuppressive or immunotherapeutic regimen,wherein said CHO GAA is the precursor form of human acid α-glucosidase.16. The method according to claim 15, wherein said immunosuppressive orimmunotherapeutic regimen is administered prior to any administration ofsaid CHO GAA.